Company GENFIT Other OTC

Equities

GNFTF

FR0004163111

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades.

The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).

EUR in Million	2022	Weight	2023	Weight	Delta
Research and Development of Innovative Medicines and Diagnostic Solutions 100.0 %	20	100.0 %	29	100.0 %	+41.45%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	20	100.0 %	29	100.0 %	+41.45%

Managers	Title	Age	Since
Pascal Prigent CEO	Chief Executive Officer	56	01/18/01
Jean-François Mouney FOU	Founder	68	01/99/01
Thomas Baetz DFI	Director of Finance/CFO	50	22/21/22
John Brozek CTO	Chief Tech/Sci/R&D Officer	47	-
Stefanie Magner CMP	Compliance Officer	43	01/16/01
Pascal Caisey COO	Chief Operating Officer	56	01/19/01
Carol L. Addy CTO	Chief Tech/Sci/R&D Officer	64	09/19/09
Meriam Kabbaj CTO	Chief Tech/Sci/R&D Officer	50	01/22/01
Dean Hum CTO	Chief Tech/Sci/R&D Officer	61	01/00/01
Jean-Christophe Marcoux IRC	Investor Relations Contact	47	01/15/01

Members of the board	Title	Age	Since
Jean-François Tiné BRD	Director/Board Member	67	04/21/04
Jean-François Mouney FOU	Founder	68	01/99/01
Florence Séjourné FOU	Founder	52	15/99/15
Xavier Guille des Buttes BRD	Director/Board Member	82	18/06/18
Catherine Larue BRD	Director/Board Member	68	16/17/16
Anne-Hélène Monsellato BRD	Director/Board Member	56	16/17/16
Katherine Kalin BRD	Director/Board Member	61	07/20/07
Eric Baclet BRD	Director/Board Member	64	07/20/07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,834,983	43,240,391 ( 86.77 %)	0	86.77 %

Name	Equities	%	Valuation
IPSEN 7.997 %	3,985,239	7.997 %	14 M $
Tang Capital Management LLC 4.917 %	2,450,404	4.917 %	8 M $
Biotech Avenir SAS 3.790 %	1,888,618	3.790 %	6 M $
Universite de Lille II Foundation 1.307 %	651,250	1.307 %	2 M $
Sunny Asset Management SA 0.2408 %	120,000	0.2408 %	410 592 $
Jean-François Mouney 0.0935 %	46,594	0.0935 %	159 426 $
Meeschaert Asset Management SA 0.0761 %	37,911	0.0761 %	129 716 $
Ecofi Investissements SA 0.0723 %	36,042	0.0723 %	123 321 $
OFI Invest Asset Management SA 0.0625 %	31,128	0.0625 %	106 508 $
Pascal Prigent 0.0616 %	30,708	0.0616 %	105 070 $

Name	Equities	%	Valuation
Millennium Management LLC 0.0596 %	29,717	0.0596 %	102 524 $
Morgan Stanley & Co. International Plc 0.0571 %	28,464	0.0571 %	98 201 $
Citadel Securities GP LLC 0.0338 %	16,833	0.0338 %	58 074 $
Optiver Holding BV 0.001932 %	963	0.001932 %	3 322 $
RhumbLine Advisers LP 0.001360 %	678	0.001360 %	2 339 $
Qube Research & Technologies Ltd. (France) 0.000197 %	98	0.000197 %	338 $

Genfit SA

Parc Eurasante 885, Avenue Eugène Avinée

59120, Loos

+33 3 20 16 40 00

http://www.genfit.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.63%	5.09TCr
IQVIA HOLDINGS INC.	-0.09%	4.21TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-4.96%	2.92TCr
ICON PUBLIC LIMITED COMPANY	+11.18%	2.6TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	1.89TCr
BIO-TECHNE CORPORATION	+8.61%	1.32TCr
UNITED THERAPEUTICS CORPORATION	+24.73%	1.22TCr
MEDPACE HOLDINGS, INC.	+28.31%	1.22TCr

Other Biotechnology & Medical Research